Funding data limitations:

Non-disclosed deals not captured: Some funding (especially large Series C+ rounds) is announced but not detailed. The July 2025–June 2026 sample captures declared rounds only.
Private capital not included: Family offices, corporate venture capital, and other non-VC sources are not systematically tracked.
Geographic bias: Data heavily reflects North American and Europe-focused companies. APAC, LMIC, and African startups may be undercounted.
Snapshot vs. trend: A 12-month window captures current flows but not long-term trajectory. The market is evolving; 2027 may look different.

Market forecast limitations:

Conditional on regulatory approval: $101.6B longevity biotech drug market assumes multiple approvals for aging-targeted drugs. If regulatory pathways remain unclear, actual market will be smaller.
Third-party estimates: MarketIntelo and similar firms make assumptions about adoption, pricing, and indication breadth. These may not materialize.

Deck 6: Methods & Appendix